MARKET NEWS

Adynxx Announces Merger Agreement With Alliqua BioMedical
ExCellThera’s Lead Technology Receives FDA Regenerative Medicine Advanced Therapy Designation 
Vyome Therapeutics Begins Dosing in Phase 2 Trial of Bactericidal Antibiotic Topical Gel
OmniSeq & LabCorp Extend Exclusive Distribution Pact & Complete Follow-On Investment Agreement
ChemioCare Announces Initiation of PETT-Based (Permeation Enhanced Transdermal Technology) Lenalidomide Program
Catalent Invests $14 Million at its Softgel Facility

  FEATURED EDITORIAL

  COMPANY PROFILE

Pfizer CentreOne is a global contract manufacturer that focuses on API synthesis, sterile injectables fill-finish and highly potent solids. For more than 40 years, we’ve manufactured complex compounds for our biopharmaceutical partners. Our dedicated team of contract manufacturing experts guide your drug safely from development through commercialization, backed by the quality and resources of Pfizer. Click here for more.

  EXCLUSIVE ONLINE CONTENT

QPS Outpaces Market Growth for Phase I Clinical Trials

QPS Outpaces Market Growth for Phase I Clinical Trials

QPS, a global contract research organization (CRO) providing discovery, preclinical, and clinical drug development services, recently announced its successful implementation of ClinSpark, an eSource technology platform for Phase I automation, to support double-digit growth in Phase I clinical trials.

Autolus Therapeutics Receives FDA Orphan Drug Designation

Autolus Therapeutics Receives FDA Orphan Drug Designation

Autolus Therapeutics plc recently announced the US FDA has granted orphan drug designation to autologous enriched T-cells genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 (AUTO3) for the treatment of acute lymphoblastic leukemia (ALL).

Cambrex Completes New Quality Control Laboratory for Generic API Development in Milan

Cambrex Completes New Quality Control Laboratory for Generic API Development in Milan

Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, recently announced that it had opened a new 120m2 quality control (QC) laboratory at its site in Paullo, Milan, Italy.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 8 – Prefilled Syringes
May 15 – Particle Design Technology